Equivalentie design: Difference between revisions

From Wikistatistiek
Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:
*[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2351444&blobtype=pdf B. Jones, P. Jarvis, J. A. Lewis, and A. F. Ebbutt, Trials to assess equivalence: the importance of rigorous methods, BMJ. 1996 July 6; 313(7048): 36–39]
*[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2351444&blobtype=pdf B. Jones, P. Jarvis, J. A. Lewis, and A. F. Ebbutt, Trials to assess equivalence: the importance of rigorous methods, BMJ. 1996 July 6; 313(7048): 36–39]


*[http://www.annals.org/cgi/reprint/133/6/455.pdf Temple R., Ellenberg S, Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues,  Ann Intern Med. 2000 Sep 19;133(6):455-63]
*[http://www.annals.org/cgi/reprint/133/6/455.pdf Temple R., Ellenberg S, Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and Scientific Issues,  Ann Intern Med. 2000 Sep 19;133(6):455-63]


*[http://www.annals.org/cgi/content/full/133/6/464 Ellenberg SS, Temple R., Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases, Ann Intern Med. 2000 Sep 19;133(6):464-70]
*[http://www.annals.org/cgi/content/full/133/6/464 Ellenberg SS, Temple R., Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases, Ann Intern Med. 2000 Sep 19;133(6):464-70]

Revision as of 10:51, 19 August 2009